ALNYLAM PHARMACEUTICALS, INC. Operating Expenses
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Operating Expenses of $222.26 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2018-08-02
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2018-06-30 was $222.26M, a 62.94% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2018-03-31 was $169.30M, a 34.93% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2017-12-31 was $185.23M, a 39.39% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2017-09-30 was $142.90M, a 18.76% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for fiscal 2017 was $590.00M, a 25.07% increase from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for fiscal 2016 was $471.75M, a 39.94% increase from fiscal 2015.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for fiscal 2015 was $337.11M, a 26.00% decline from fiscal 2014.
- ALNYLAM PHARMACEUTICALS, INC. operating expenses for fiscal 2014 was $455.54M, a 225.13% increase from fiscal 2013.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2018-06-30 | $222.26M 10-Q · filed 2018-08-02 | $391.56M 10-Q · filed 2018-08-02 | $576.79M derived: sum of 3 quarters · filed 2018-08-02 | $719.69M derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | $169.30M 10-Q · filed 2018-05-04 | $354.53M derived: sum of 2 quarters · filed 2018-05-04 | $497.43M derived: sum of 3 quarters · filed 2018-05-04 | $633.83M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-12-31 | $185.23M 10-K · filed 2018-02-15 | $328.12M derived: sum of 2 quarters · filed 2018-02-15 | $464.53M derived: sum of 3 quarters · filed 2018-08-02 | $590.00M 10-K · filed 2018-02-15 |
| 2017-09-30 | $142.90M 10-K · filed 2018-02-15 | $279.30M derived: sum of 2 quarters · filed 2018-08-02 | $404.77M 10-Q · filed 2017-11-07 | $537.66M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-06-30 | $136.41M 10-Q · filed 2018-08-02 | $261.88M 10-Q · filed 2018-08-02 | $394.76M derived: sum of 3 quarters · filed 2018-08-02 | $515.09M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $125.47M 10-Q · filed 2018-05-04 | $258.36M derived: sum of 2 quarters · filed 2018-05-04 | $378.69M derived: sum of 3 quarters · filed 2018-05-04 | $479.84M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $132.89M 10-K · filed 2018-02-15 | $253.21M derived: sum of 2 quarters · filed 2018-02-15 | $354.37M derived: sum of 3 quarters · filed 2018-02-15 | $471.75M 10-K · filed 2018-02-15 |
| 2016-09-30 | $120.33M 10-K · filed 2018-02-15 | $221.49M derived: sum of 2 quarters · filed 2018-02-15 | $338.86M 10-Q · filed 2017-11-07 | $438.92M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $101.16M 10-K · filed 2018-02-15 | $218.53M 10-Q · filed 2017-08-09 | $318.60M derived: sum of 3 quarters · filed 2018-02-15 | $403.25M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $117.37M 10-K · filed 2018-02-15 | $217.44M derived: sum of 2 quarters · filed 2018-02-15 | $302.09M derived: sum of 3 quarters · filed 2018-02-15 | $383.72M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $100.06M 10-K · filed 2017-02-15 | $184.72M derived: sum of 2 quarters · filed 2017-02-15 | $266.35M derived: sum of 3 quarters · filed 2017-02-15 | $337.11M 10-K · filed 2018-02-15 |
| 2015-09-30 | $84.65M 10-K · filed 2017-02-15 | $166.28M derived: sum of 2 quarters · filed 2017-02-15 | $237.04M 10-Q · filed 2016-11-03 | $306.77M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $81.63M 10-K · filed 2017-02-15 | $152.39M 10-Q · filed 2016-08-04 | $222.12M derived: sum of 3 quarters · filed 2017-02-15 | $278.29M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $70.76M 10-K · filed 2017-02-15 | $140.49M derived: sum of 2 quarters · filed 2017-02-15 | $196.66M derived: sum of 3 quarters · filed 2017-02-15 | $248.96M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $69.73M 10-K · filed 2016-02-12 | $125.90M derived: sum of 2 quarters · filed 2016-02-12 | $178.20M derived: sum of 3 quarters · filed 2016-02-12 | $455.54M 10-K · filed 2017-02-15 |
| 2014-09-30 | $56.17M 10-K · filed 2016-02-12 | $108.47M derived: sum of 2 quarters · filed 2016-02-12 | $385.81M 10-Q · filed 2015-11-09 | $426.25M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $52.30M 10-K · filed 2016-02-12 | $329.64M 10-Q · filed 2015-08-07 | $370.08M derived: sum of 3 quarters · filed 2016-02-12 | $411.30M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $277.34M 10-K · filed 2016-02-12 | $317.78M derived: sum of 2 quarters · filed 2016-02-12 | $359.00M derived: sum of 3 quarters · filed 2016-02-12 | $389.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $40.44M 10-K · filed 2015-02-13 | $81.66M derived: sum of 2 quarters · filed 2015-02-13 | $111.66M derived: sum of 3 quarters · filed 2015-02-13 | $140.11M 10-K · filed 2016-02-12 |
| 2013-09-30 | $41.23M 10-K · filed 2015-02-13 | $71.22M derived: sum of 2 quarters · filed 2015-02-13 | $99.67M 10-Q · filed 2014-11-06 | $196.51M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $30.00M 10-K · filed 2015-02-13 | $58.45M 10-Q · filed 2014-08-08 | $155.29M derived: sum of 3 quarters · filed 2015-02-13 | $190.19M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $28.45M 10-K · filed 2015-02-13 | $125.29M derived: sum of 2 quarters · filed 2015-02-13 | $160.20M derived: sum of 3 quarters · filed 2015-02-13 | $193.15M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $96.84M 10-K · filed 2014-02-20 | $131.75M derived: sum of 2 quarters · filed 2014-02-20 | $164.70M derived: sum of 3 quarters · filed 2014-02-20 | $196.18M 10-K · filed 2015-02-13 |
| 2012-09-30 | $34.91M 10-K · filed 2014-02-20 | $67.86M derived: sum of 2 quarters · filed 2014-02-20 | $99.34M 10-Q · filed 2013-11-07 | $133.38M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $32.95M 10-K · filed 2014-02-20 | $64.43M 10-Q · filed 2013-08-09 | $98.47M derived: sum of 3 quarters · filed 2014-02-20 | $131.70M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $31.48M 10-K · filed 2014-02-20 | $65.52M derived: sum of 2 quarters · filed 2014-02-20 | $98.75M derived: sum of 3 quarters · filed 2014-02-20 | $132.48M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $34.04M 10-K · filed 2013-02-19 | $67.27M derived: sum of 2 quarters · filed 2013-02-19 | $101.00M derived: sum of 3 quarters · filed 2013-02-19 | $137.57M 10-K · filed 2014-02-20 |
| 2011-09-30 | $33.23M 10-K · filed 2013-02-19 | $66.96M derived: sum of 2 quarters · filed 2013-02-19 | $103.53M 10-Q · filed 2012-11-05 | $137.14M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $33.73M 10-K · filed 2013-02-19 | $70.31M 10-Q · filed 2012-08-08 | $103.91M derived: sum of 3 quarters · filed 2013-02-19 | $140.30M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $36.57M 10-K · filed 2013-02-19 | $70.17M derived: sum of 2 quarters · filed 2013-02-19 | $106.57M derived: sum of 3 quarters · filed 2013-02-19 | $144.81M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $33.60M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $70.00M derived: sum of 2 quarters · filed 2013-02-19 | $108.24M derived: sum of 3 quarters · filed 2013-02-19 | $144.11M 10-K · filed 2013-02-19 |
| 2010-09-30 | $36.40M 10-Q · filed 2011-11-03 | $74.64M derived: sum of 2 quarters · filed 2011-11-03 | $110.51M 10-Q · filed 2011-11-03 | $145.20M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | $38.24M 10-Q · filed 2011-08-03 | $74.11M 10-Q · filed 2011-08-03 | $108.81M derived: sum of 3 quarters · filed 2012-02-13 | $142.71M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | $35.87M 10-Q · filed 2011-05-05 | $70.56M derived: sum of 2 quarters · filed 2012-02-13 | $104.46M derived: sum of 3 quarters · filed 2012-02-13 | $151.48M derived: sum of 4 quarters · filed 2012-02-13 |
| 2009-12-31 | $34.70M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | $68.59M derived: sum of 2 quarters · filed 2012-02-13 | $115.61M derived: sum of 3 quarters · filed 2012-02-13 | $148.64M 10-K · filed 2012-02-13 |
| 2009-09-30 | $33.90M 10-Q · filed 2010-11-04 | $80.91M derived: sum of 2 quarters · filed 2010-11-04 | $113.95M 10-Q · filed 2010-11-04 | |
| 2009-06-30 | $47.01M 10-Q · filed 2010-08-05 | $80.05M 10-Q · filed 2010-08-05 | ||
| 2008-12-31 | $124.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |